Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
67,127.10 +1,284.55 (+1.95%) CMC Crypto 200
1,371.90 -1.95 (-0.14%)
RMD Jul 2024 185.000 call
| Previous close | 37.06 |
| Open | 37.06 |
| Bid | 34.90 |
| Ask | 36.70 |
| Strike | 185.00 |
| Expiry date | 2024-07-19 |
| Day's range | 37.06 - 37.06 |
| Contract range | N/A |
| Volume | |
| Open interest | 122 |
ZacksHaemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
GlobeNewswireATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights: Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV) in Opioid Users – a European Registry Sunday May 19, 2024, 9:15 a.m. - 11:15 a.m., SDCC 32A-BPresented
ZacksWhat Makes ResMed (RMD) a New Strong Buy Stock
ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
